Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition

Christopher Patriquin, Jun-Ho Jang, Lisa Aurand, Deepak Taneja, Andrew Magyar, Bradley Dain, Karoline Meagher, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2024) 144 (Supplement 1): 306.

https://doi.org/10.1182/blood-2024-194610

Published: 2024

Journal Articles

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Richard J. Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Kosalai Mohan, Brian Senk, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2023) 142 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2023-188671

Published: 2023

Journal Articles

A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab

Richard Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Bradley Dain, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2022) 140 (Supplement 1): 8174–8175.

https://doi.org/10.1182/blood-2022-166547

Published: 2022

Journal Articles

A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Jun Ho Jang, Raymond Wong, Rodrigo Pavani, Lisa Aurand, Bradley Dain, Lorah Perlee, Amal Souttou, Jonathan Weyne, Richard Kelly

Blood (2022) 140 (Supplement 1): 8172–8173.

https://doi.org/10.1182/blood-2022-163236

Published: 2022